RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase

ABSTRACT: Abstract

Background

Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.

Objective

Report long-term safety and efficacy outcomes with OOC from the open-label extension (OLE) of MPOWERED.

Methods

Patients were eligible for and could voluntarily enroll into the OLE if they had completed the 15-month core treatment phase of MPOWERED (6-month Run-in phase plus 9-month randomized controlled

SUBMITTER:  

PROVIDER: S-EPMC9625520 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature